Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Daiichi Sankyo Company, Limited - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
DSNKY
Over the counter
2834
www.daiichisankyo.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Daiichi Sankyo Company, Limited
IHH Healthcare's damages against Daiichi could reach $1.25 billion, expert report says
- Feb 6th, 2025 10:28 am
Survey Reveals: 88% of Western Europeans Would Like Better Information on Breast Cancer, Misconceptions and Lack of Awareness of the Disease Still Prevail
- Feb 4th, 2025 7:00 am
Datopotamab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
- Jan 31st, 2025 1:00 pm
Hiroyuki Okuzawa succeeds Sunao Manabe as Daiichi Sankyo CEO
- Jan 31st, 2025 11:11 am
Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer
- Jan 31st, 2025 4:05 am
TROPION-Lung12 Phase 3 Trial Initiated Evaluating DATROWAY® as Part of Adjuvant Regimen for Patients with Early-Stage Non-Small Cell Lung Cancer at High Risk of Relapse
- Jan 31st, 2025 4:00 am
FDA expands Enhertu approval to include HER2-ultralow breast cancer patients
- Jan 29th, 2025 4:26 pm
FDA Expands Label of AZN's Enhertu for New Breast Cancer Indication
- Jan 28th, 2025 4:11 pm
ENHERTU® Approved in the U.S. as First HER2 Directed Therapy for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following Disease Progression After One or More Endocrine Therapies
- Jan 27th, 2025 11:00 pm
FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients
- Jan 21st, 2025 5:54 pm
DATROWAY® Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
- Jan 17th, 2025 10:35 pm
Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m
- Jan 14th, 2025 7:39 pm
Daiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbH
- Jan 13th, 2025 4:00 pm
Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
- Jan 13th, 2025 7:00 am
AZN, Daiichi Withdraw EU Filing for Dato-DXd in Nonsquamous NSCLC
- Dec 26th, 2024 3:19 pm
AstraZeneca, Daiichi Sankyo withdraw EU application for lung cancer treatment
- Dec 26th, 2024 11:40 am
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn
- Dec 24th, 2024 7:00 am
Daiichi Sankyo doses first subject in Phase III AML therapy trial
- Dec 11th, 2024 12:26 pm
AZN, Daiichi's ADC Gets FDA Breakthrough Tag for EGFR-Mutated NSCLC
- Dec 10th, 2024 2:44 pm
QuANTUM-Wild Phase 3 Trial of VANFLYTA® Initiated in Patients with Newly Diagnosed FLT3-ITD Negative AML
- Dec 10th, 2024 1:00 pm
Scroll